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Abstract
Huntington’s disease, an inherited neurodegenerative disorder, results from abnormal polyglutamine extension in the N-terminal
region of the huntingtin protein. This mutation causes preferential degeneration of striatal projection neurons. We previously
demonstrated, in vitro, that dopaminergic D2 receptor stimulation acted in synergy with expanded huntingtin to increase aggre-
gates formation and striatal death through activation of the Rho/ROCK signaling pathway. In vivo, in a lentiviral-mediated model
of expanded huntingtin expression in the rat striatum, we found that the D2 antagonist haloperidol protects striatal neurons
against expanded huntingtin-mediated toxicity. Two variant transcripts are generated by alternative splicing of the of D2 receptor
gene, the D2R-Long and the D2R-Short, which are thought to play different functional roles. We show herein that overexpression
of D2R-Short, but not D2R-Long in cell lines is associated with activation of the RhoA/ROCK signaling pathway. In striatal neu-
rons in culture, the selective D2 agonist Quinpirole triggers phosphorylation of cofilin, a downstream effector of ROCK, which is
abrogated by siRNAs that knockdown both D2R-Long and D2R-Short, but not by siRNAs targeting D2R-Long alone. Aggregate
formation and neuronal death induced by expanded huntingtin, were potentiated by Quinpirole. This D2 agonist-mediated effect
was selectively inhibited by the siRNA targeting both D2R-Long and D2R-Short but not D2R-Long alone. Our data provide evi-
dence for a specific coupling of D2R-Short to the RhoA/ROCK/cofilin pathway, and its involvement in striatal vulnerability to
expanded huntingtin. A new route for targeting Rho-ROCK signaling in Huntington’s disease is unraveled with our findings.
Introduction
Huntington’s disease (HD) is an inherited neurodegenerative disor-
der resulting from abnormal polyglutamine extension in the N-term-
inal region of the huntingtin protein (Exp-HTT; The Huntington’s
Disease Collaboration Group, 1993). It is characterized by chorea,
psychiatric disturbances, and cognitive impairments (Roze et al.,
2008). Although Exp-HTT is expressed ubiquitously in the brain, a
selective vulnerability of striatal neurons, which is causal in the neu-
ropathology, is now well established in the disease. The dopaminer-
gic hypothesis of this vulnerability arose during the past years. First,
the striatum receives the densest dopaminergic (DA) innervation of
the brain, and striatal neurodegeneration in HD is positively corre-
lated with the gradient of DA in its rostro-caudal extension (Vonsat-
tel et al., 1985). Second, in animal or cellular models, an
exaggerated increase of DA produces spontaneous striatal death and
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HD-like behaviors (Luo et al., 1998; Cyr et al., 2003). Furthermore,
D2 receptor (D2R) stimulation by DA acts in synergy with
Exp-HTT to increase aggregate formation, neuritic retraction,
mitochondrial dysfunctions, and striatal death (Charvin et al., 2005;
Benchoua et al., 2008). In vivo, chronic treatment with the D2R
antagonist haloperidol protects against striatal dysfunctions induced
by Exp-HTT in a lentiviral-based model system in rats (Charvin
et al., 2008).
D2Rs belong to the structurally related G-protein-coupled recep-
tors family, which are characterized by seven transmembrane seg-
ments (De Mei et al., 2009). D2Rs are classically identified as
inhibitors of cyclic AMP production and activation of PKA via their
coupling to Gai subunits (De Mei et al., 2009). D2Rs also affect
many downstream effectors including K+ channels (Greif et al.,
1995), L-type Ca2+ channels and phospholipase C (PLC; Hernan-
dez-Lopez et al., 2000), glutamate release (Bamford et al., 2004;
Yin & Lovinger, 2006), and intracellular signaling pathways includ-
ing mitogen-activated protein kinases and Akt (Brami-Cherrier
et al., 2002; reviewed in Vallone et al., 2000; Neve et al., 2004).
We made the original observation that D2Rs were coupled to the
Rho-ROCK signaling pathway, and that D2R-mediated activation of
this pathway was responsible for a potentiation of ExpHTT-induced
neuritic retraction and striatal neuron death (Deyts et al., 2009).
Two variant transcripts are generated by alternative splicing of the
D2Rs gene and code for the D2R Long and D2R Short isoforms,
respectively (De Mei et al., 2009). The D2R Short isoform differs
from D2R Long by the deletion of 29 amino acids in the third intracel-
lular loop of the receptor. These spliced variants are expressed in the
same cell types and exhibit similar pharmacological characteristics
with no isoform-specific pharmacological ligands identified so far.
They possess a differential subcellular distribution, with D2R Short
being preferentially presynaptic inhibitory autoreceptors and playing a
preferential role in release modulation, (Lindgren et al., 2003)
whereas D2R Long are predominantly postsynaptic receptors associ-
ated with G-protein-dependent and -independent intracellular signal-
ing (De Mei et al., 2009). Because D2R-induced potentiation of
ExpHtt-induced striatal phenotype (aggregate formation and striatal
death) was totally blocked by selective inhibition or knockdown of
Rho-ROCK signaling pathway (Deyts et al., 2009), we investigated
herein a possible specific coupling of D2R Short or D2R Long to the
Rho/ROCK signaling pathway and striatal vulnerability in HD.
Materials and methods
HEK293 cell culture and transfection
HEK293 cells were cultured and maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum (FBS) and 0.1% penicillin–
streptomycin. The day before transfection, the cells were plated in
p100 mm dishes in DMEM without antibiotics. HEK293 cells were
then transiently transfected using Lipofectamine (Invitrogen) with
4 lg of plasmids encoding N-terminal YFP-tagged D2 receptor iso-
forms, YFP-D2R Long and YFP-D2R Short (generously provided
by Dr Philippe Vernier (CNRS, France) or empty plasmid during
24 h later.
Rho activity assay
Rho activation was analyzed using Rho assay kit (Upstate Biotech-
nology, Waltham, CA, USA). After overnight starvation in 0.1%
FBS, HEK293 cells expressing D2R Short or D2R Long isoforms
of D2R or the empty vector were stimulated with Quinpirole
(10 lM, RBI) or Dopamine (DA; 100 lM, Calbiochem, San Diego,
CA, USA) for 5 min at 37 °C. Cells were then lysed in 10% glyc-
erol, 50 mM Tris pH 7.2, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, 500 mM NaCl, 10 mM MgCl2, and complete
protease inhibitor cocktail tablets (Roche, Indianapolis, IN, USA)
for 15 min at 4 °C in a rotator. Homogenates were clarified by cen-
trifugation at 13 000 g at 4 °C for 5 min. Rho activity was then
measured according to the manufacturer’s instructions. Rho-GTP
was subjected to SDS-PAGE followed by western blotting with
mouse anti-Rho (-A,-B,-C; 1/250; Millipore, Billerica, MA, USA).
The bands were quantified by densitometric analysis using a dedi-
cated macro application of SCION IMAGE software (Scion Corp., Fred-
erick, MD, USA) and normalized to Total-Rho expression.
RNA interference
siRNAs were designed to interfere with the expression of both D2R
isoforms (siRNA D2R Total: CCAGAGAGGACCCGGTAT) or
only the D2R Long isoform (D2R Long siRNA: CCAGTGAA-
CAGGCGGAGAA). Neurons were transfected at days in vitro
(DIV4) with 50 nM of D2R Total siRNA, D2R Long-specific, or
Control siRNA (Cont siRNA #2, Ambion, Austin, TX, USA). The
specificity of siRNAs was validated in primary striatal cultures 72 h
after transfection. When indicated, primary neurons were transfected
(DIV7) with either wild-type (HTT) or expanded-HTT (Exp-HTT;
see methods below). Drug treatment and evaluation of aggregates or
death were performed as indicated above.
RNA isolation and RT-PCR
RNA isolation and RT-PCR methods were performed as previously
described (Deyts et al., 2009). The nucleotide sequences of the
primers used to specifically amplify D2R Long and D2R Short
receptors were as follows: D2R Long, forward 50-AACTGTACC
CACCCTGAGGA-30, reverse 50-GTTGCTATGTAGACCGTG-30;
D2R Short, forward 50-CACCACTCAAGGATGCTGCCCG-30,
reverse 50-GTTGCTATGTAGACCGTG-30. ARP (Acidic Ribosomal
Protein) was used as a housekeeping gene: ARP, forward 50-GAA
CGTCGTCTTCGTGTTCA-30, reverse 50-AAAACCTGGACGAAG
GAGGT-30.
Primary striatal culture
Striatal neurons were dissected out from E14 embryos from preg-
nant Swiss mice (Janvier, France) as previously described (Charvin
et al., 2005) and in accordance with the European Community
guidelines on the Care and Use of Laboratory Animals (86/609/
EEC). Experiments were approved by the local ethic committee
(reference 01435.02). For transfection assays, 0.8 lg of GFP-
tagged plasmids encoding the first exon of human Huntingtin
(HTT) containing either 25 or 103 continuous CAA or CAG
repeats (HTT and Exp-HTT, respectively) was transfected at DIV
7, using Lipofectamine (Invitrogen). Three hours and a half after
transfection, the medium was removed and replaced by fresh cul-
ture medium containing DA (100 lM) or Quinpirole (10 lM).
Aggregate formation was evaluated 12 h after transfection by
counting neurons expressing aggregated GFP vs. the total number
of GFP-positive neurons. D2R agonist-induced potentiation of cell
death was evaluated 24 h after transfection. Neurons containing
condensed or fragmented nuclei, based on Hoechst labeling, were
scored as dying cells.
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Immunocytochemistry
Striatal neurons were fixed in 2% paraformaldehyde in PBS for
40 min at room temperature (RT) and permeabilized with methanol/
acetone (1 : 1) for 10 min at 4 °C. After 1-h incubation with block-
ing buffer (10% normal goat serum in PBS, RT), cells were incu-
bated overnight with primary antibodies in PBS at 4 °C; mouse
anti-MAP-2 (1/1000, Sigma Aldrich, St.Louis, MO, USA) or rabbit
anti-P-cofilin (1/500, Cell Signaling, Technology, Ipswich, MA,
USA). Cells were washed with PBS and incubated for 2 h at RT
with corresponding Alexa-conjugated secondary antibodies (1/1000,
Jackson Laboratories, Bar Harbor, Maine, USA). Nuclei were
stained with Hoechst (1/20000 in PBS, Invitrogen). Coverslips were
mounted using Mowiol (Calbiochem) and examined with a Leica
DM4000B fluorescence microscope (209). In each experiment, con-
ducted a minimum of three times, a total of at least 10 fields were
randomly analyzed using IMAGEPRO-PLUS software.
Statistical analysis
Data are presented as mean  SEM. Statistics were performed using
GRAPHPAD PRISM (GraphPad Software Inc., San Diego, CA). One-way
or two-way ANOVA followed by post hoc Bonferroni’s test were car-
ried out for statistical analyses as indicated in the results. The differ-
ence between comparisons was considered to be significant when
P < 0.05.
Results
Overexpression of D2R Short, but not D2R Long, activates
the RhoA/ROCK signaling in HEK293 cells
We previously showed that DA and the D2 agonist Quinpirole acti-
vate the RhoA/ROCK signaling pathway in primary cultures of stri-
atal neurons (Deyts et al., 2009). In order to investigate a possible
differential coupling of either D2R Short or D2R Long to the RhoA/
ROCK signaling pathway, we first used a heterologous cellular sys-
tem cDNAs encoding these D2R-specific isoforms tagged to YFP,
were transfected in HEK293 cells, and allowed expression of the
receptors that were trafficked to the plasma membrane, as expected
(Fig. 1A). We next measured Rho activity by measuring RhoA-GTP
levels relative to Total-RhoA in transfected cells (Fig. 1B–C). After
overnight serum deprivation, cells were treated with Quinpirole
Control
Control
Co
nt
ro
l
D2
R
Sh
or
t
D2
R
Lo
ng
Co
nt
ro
l
D2
R
Sh
or
t
D2
R
Lo
ng
7.5
R
el
at
iv
e 
rh
o 
ac
tiv
ity
5
2.5
0.0
7.5
R
el
at
iv
e 
rh
o 
ac
tiv
ity
5
2.5
0.0
** *
Quinpirole
Control
Dopamine
– + + +– –
D2R Short D2R Long Control
Dopamine
Rho-GTP
Total Rho
Rho-GTP
Total Rho
– + + +– –
D2R Short D2R Long
Quinpirole
Control
– + + +
P-ERK
ERK
– –
D2R Short D2R Long
Quinpirole
A
B
D
F
E
C
Fig. 1. Dopamine D2R Short specific coupling to the RhoA/ROCK signaling pathway in HEK293 cells. HEK 293 cells were transiently transfected with YFP-
tagged D2R Short and D2R Long (right panel) during 24 h. (A) Epifluorescence images showing the YFP-tagged D2R Short (left panel) and D2R Long (right
panel) receptors expression in HEK293 cells. Note that both D2R Short and D2R Long are expressed at the plasma membrane. Scale bar: 10 lm. (B and C)
RhoA-GTP pull-down assay with Rhotekin-GST and western blot detection of RhoA-GTP (up) and TOTAL-RhoA (down) were performed in D2R Short or
D2R Long transfected cells after 5 min of Quinpirole 10 lM (B) or 100 lM DA (C) treatment. Control lanes correspond to cells transfected with an empty vec-
tor. (D and E) Quantification of RhoA-GTP activity normalized to TOTAL-RhoA protein was performed by densitometric analysis from three independent
experiments after Quinpirole (D) or Dopamine (E) treatment. (D–E) Two-way ANOVA followed by Bonferroni’s post hoc analysis (n = 3 independent experi-
ments; *P < 0.05, **P < 0.01 compared with non-treated cells. (F) Quinpirole-induced ERK phosphorylation in D2R Short- and D2R Long-expressing cells by
comparison with YFP-alone transfected cells (Control). Quinpirole treatment (10 lM, 5 min) was able to induce ERK phosphorylation in D2R Long and D2R
Short receptors-expressing cells. No changes in total ERK protein were detected.
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(10 lM; Fig. 1B) or Dopamine (DA; 100 lM; Fig. 1C) for 5 min.
RhoA was activated by Quinpirole in D2R Short-expressing cells
(P = 0.0028 between Control and Quinpirole-treated cells) but not
D2R Long-expressing cells (P > 0.9999 non-significant between
Control and Quinpirole-treated cells; Fig. 1B and D). Similar results
were obtained in DA-treated cells (P = 0.0292 between D2R Short-
expressing cells treated or not with Quinpirole; Fig. 1C and E). In
order to verify the functionality of the transfected D2Rs, ERK activa-
tion by Quinpirole was studied. As expected, a robust induction of
ERKs phosphorylation was observed in response to Quinpirole in
both D2R Short and D2R Long transfected cells (Fig. 1F). These
results clearly demonstrate a specific coupling of D2R Short but not
D2R Long to RhoA activation in HEK293 cells.
siRNAs strategy for knocking down D2 receptors in striatal
neurons in culture
We next designed a siRNA-based strategy aimed at silencing D2Rs
expression in striatal neurons in culture. As a first step, we analyzed
endogenous expression levels of mRNAs encoding D2R Short and
D2R Long, in primary striatal neurons in culture (DIV 7 and DIV
15; Fig. 2A). To amplify the D2R Long isoform, we used a forward
primer annealing the exon 6, which is lost in D2R Short. To amplify
D2R Short, the forward primer was designed in order to specifically
bind to the spliced junction between exons 5 and 7. Reverse primers
were designed to anneal with exon 7, common to both isoforms.
RT-PCR showed that mRNAs encoding D2R Short and D2R Long
were expressed in striatal neurons in culture (Fig. 2A). Then we
designed siRNAs in order to knockdown D2Rs (Fig. 2B). D2R
Total siRNA corresponded to a sequence of exon 7 common to both
D2R Short and D2R Long mRNA sequences. The siRNA target
sequence for specific knockdown of D2R Long mRNA was located
in the exon 6, and thus absent in the D2R Short splice variant. Vali-
dation of these two siRNAs (D2R Total and D2R Long) was
achieved after transfection in striatal neurons. As expected, semi-
quantitative RT-PCR showed that D2R Long siRNA knocked down
D2R Long but not D2R Short expression (Fig. 2C), while D2R
Total siRNA decreased expression of both isoforms (Fig. 2D).
Fig. 2. D2R Long and D2R Short expression levels in primary striatal neurons and validation of D2 receptors specific siRNAs. (A) RT-PCR with specific pri-
mers showed that D2S and D2L mRNAs are expressed in E14 striatal neurons in culture at DIV7 and DIV15. (B) siRNA target sequences and designed strat-
egy used to knockdown both isoforms of D2 receptors (D2R Total siRNA) or specifically the Long isoform (D2R Long siRNA). (C–D) Validation by
semiquantitative RT-PCR of D2R Long (C) and D2R Total (D) siRNA efficacy. Lower panels show mRNA levels of the housekeeping gene ARP (acidic ribo-
somal protein). (E–F) Quantification of D2L (E) and D2S (F) mRNA levels after siRNA transfections. Reported are the ratios of D2R over ARP mRNAs. As
expected, D2L but not D2S mRNA expression is abolished by D2R Long siRNA (C) compare upper and middle panels; (E–F) compare Control and D2R Long
siRNA). Both D2R Short and D2R Long mRNAs are down-regulated by D2R Total siRNA (D) compare upper and middle panels, (E–F) compare Control and
D2R total siRNA). (E–F) Data are expressed as mean  SEM of 3–4 independent experiments. Statistical analyses were performed using one-way ANOVA fol-
lowed by Bonferroni’s post hoc analysis. n.s., non-significant; **P < 0.005 when comparing Control with D2R Long siRNA, ###P < 0.001 when comparing
Control with D2R total siRNA, °°°P < 0.001 when comparing Control siRNA with D2R Long siRNA, &&&P < 0.001 when comparing Control siRNA with
D2R total siRNA, $P < 0.05 when comparing D2R Long siRNA with D2R Total siRNA.
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Fig. 3. Comparative effect of D2R Long siRNA and D2R Total siRNA on Quinpirole-induced phosphorylation of cofilin in cultured striatal neurons. (A–C)
Representative immunofluorescence images showing MAP2 (red) and P-cofilin (green) immunoreactivity in control conditions (upper panels) or 20 min after
Quinpirole treatments (10 lM, lower panels) in striatal neurons transfected with Control siRNA (A), D2R Long siRNA (B) and D2R Total siRNA (C). Nuclei
were labeled using Hoechst (blue, merge panels). (A–C) Scale bar: 30 lm. (D) Phospho-cofilin positive neurons were calculated as a percentage relative to the
total number of neurons identified by Hoechst staining. Data are expressed as mean  SEM of three independent experiments at least. Statistics: two-way
ANOVA followed by Bonferroni post hoc analysis *P < 0.05, **P < 0,01 when comparing Control and Quinpirole-treated cells, # when comparing cells trans-
fected with Control siRNA with D2R Total siRNA. n.s.,Non-significant.
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Quantifications showed that both D2R Long and D2R Total siRNAs
decreased D2R Long mRNA levels when compared to Control
(66%, P = 0.042 and 86.8%, P = 0.0003, respectively; Fig. 2E),
while D2R Short mRNA levels were significantly decreased after
D2R Total siRNA treatment only (P = 0.0005; Fig. 2F). We
designed an siRNA targeting the spliced junction betweens exons 5
and 7, which failed to be efficient for the knowkdown of D2R Short
(data not shown). Therefore, in the following experiments, we com-
pared the effects of D2R Long and D2R Total siRNAs on D2R ago-
nist and DA-induced RhoA/ROCK signaling in striatal neurons.
Comparative role of D2R Long siRNA and D2R Total siRNA in
Quinpirole-induced phosphorylation of cofilin in striatal neurons
We previously showed that Quinpirole induces phosphorylation of
cofilin, a downstream target of RhoA/ROCK signaling, and this
phosphorylation event was totally reversed by ROCK inhibitors and
siRNA against ROCKII (Deyts et al., 2009). Thus, phosphorylated
cofilin serves as an excellent index of ROCK activation to study
D2Rs coupling to RhoA/ROCK pathway in striatal neurons.
Striatal neurons were transfected at DIV4 for 72 h with D2R
Total siRNA or D2R Long siRNA and stimulated or not with Quin-
pirole (10 lM, 20 min) or DA (not shown). The phosphorylation of
cofilin was analyzed by immunocytochemical detection owing to a
phospho-specific antibody. When transfected with the Control
siRNA, striatal neurons showed a significant increase in phospho-
cofilin immunoreactivity after Quinpirole treatment (25% vs. 9% in
untreated neurons; P = 0.001; Fig. 3A and D). In striatal neurons
transfected with D2R Long siRNA, Quinpirole induced a similar
increase in phospho-cofilin immunoreactivity (23%; P = 0.0117
between Control and Quinpirole-treated cells; Fig. 3B and D). How-
ever, knocking down both D2Rs isoforms using D2R Total siRNA
completely blocked Quinpirole-induced cofilin phosphorylation
(P = 0.0152 between Quinpirole-treated neurons expressing Control
siRNA and D2R Total siRNA; Fig. 3C and D). Altogether these
results support that stimulation of D2R Short, but not D2R Long, is
coupled to phosphorylation of cofilin in striatal neurons.
Comparative role of D2R Long siRNA and D2R Total siRNA on
Quinpirole-induced potentiation of Exp-HTT toxicity and aggregate
formation
Using primary cultures of striatal neurons expressing exon 1 of
HTT with a polyglutamine stretch (103Q: Exp-HTT) fused to
EGFP, we previously showed that DA, via D2R stimulation, poten-
tiates aggregate formation and striatal death induced by Exp-HTT
(Charvin et al., 2005). The RhoA/ROCK signaling pathway is criti-
cal for D2R-mediated effects on aggregate formation and neuronal
death (Deyts et al., 2009). We thus wished to compare the relative
contribution of D2R Long and D2R Short in these effects. In stri-
atal neurons transiently transfected with Exp-HTT, aggregate for-
mation can be easily detectable owing to GFP Tag (Fig. 4A). In
neurons co-transfected with Exp-HTT together with the Control
siRNA, a treatment with 10 lM of Quinpirole increased the per-
centage of transfected neurons containing aggregates (+36%;
Fig. 4B) and the D2R Long siRNA did not prevent this enhanced
aggregation (Fig. 4B; P > 0.9999 non-significant between Control
siRNA and D2R Long siRNA-treated cells). By contrast, the D2R
Total siRNA reversed the potentiation of aggregate formation
induced by Quinpirole (Fig. 4B; P = 0.0203), thus supporting a
specific role of D2R Short on Quinpirole-mediated aggregation of
Exp-HTT.
We next studied striatal death induced by Exp-HTT alone or in
the presence of Quinpirole. Exp-HTT produced a significant striatal
death (P = 0.0033 between untreated HTT and Exp-HTT-expressing
cells), which was potentiated by Quinpirole (P = 0.0444 between
Exp-HTT-expressing cells treated or not with Quinpirole; Fig. 4C).
D2R Long siRNA did not significantly affect the ratio of striatal
death induced by ExpHTT in the presence of Quinpirole
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Fig. 4. Comparative effect of D2R Long siRNA and D2R Total siRNA on
Quinpirole-induced potentiation of Exp-HTT toxicity and aggregate forma-
tion. (A) GFP-tagged Huntingtin (HTT) constructs (green) showing the
expression pattern of diffused wild-type HTT (25Q-HTT) and aggregated
Exp-HTT (103Q-HTT) in transfected striatal neurons (MAP2, red). (A) Scale
bar: 20 lm (B). Quantification of Quinpirole (10 lM)-induced increase of
aggregates in striatal neurons co-transfected with Exp-HTT and siRNAs
(Control, D2R Long or D2R Total). (C) The percentage of cell survival in
striatal neurons co-transfected with siRNAs (Control, D2R Long, or D2R
Total) and HTT (left panel) or Exp-HTT (right panel) was measured 24 h
after Quinpirole (10 lM) based on Hoechst labeling. Data are expressed as
mean  SEM from three independent experiments (100 transfected neurons
per condition and experiment). Statistical analyses were performed using
two-way ANOVA followed by Bonferroni’s post hoc analysis. ###P < 0.001
when comparing untreated HTT and Exp-HTT-expressing cells. $P < 0.05; $
$$P < 0.001 when comparing Quinpirole-treated HTT- and Exp-HTT-expres-
sing cells. *P < 0.05, **P < 0.005, when comparing Exp-HTT-expressing
cells treated or not with Quinpirole. οP < 0.05, when comparing Quinpirole-
treated Exp-HTT-expressing cells in the presence of Control siRNA and
D2R Total siRNA.
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(P > 0.9999 non-significant; Fig. 4C). By contrast, D2R Total
siRNA completely reversed Quinpirole-induced toxicity in Exp-
HTT-expressing neurons (P > 0.9999 non-significant between D2R
Total siRNA cells treated or not with Quinpirole), thus supporting a
preferential role of D2R-Short in this effect.
Comparative role effect of D2R Long siRNA and D2R Total siRNA
on DA-induced potentiation of Exp-HTT aggregate formation and
death
When applied at high doses (500 lM), DA induces striatal death
through a mechanism involving the formation of reactive oxygen
species (ROS) formation and the activation of pro-apoptotic path-
ways (Luo et al., 1998). This effect is accentuated with lower doses
of DA (100 lM) in Exp-HTT-expressing cells (Charvin et al.,
2005), due to a dual role on ROS production (independent of DA
receptors stimulation) and D2R stimulation. We analyzed the selec-
tive role of D2R Long siRNA and D2R Total siRNA in these
effects. In Exp-HTT-expressing neurons, DA produced a significant
increase in aggregate formation, which was not affected by D2R
Long siRNA (P > 0.9999 non-significant between Control siRNA
and D2R Long siRNA) but was completely abolished by D2R Total
siRNA (P = 0.0106 between Control siRNA and D2R Total siRNA;
Fig. 5A). These data strongly suggest a role of D2R Short in DA-
mediated aggregate potentiation.
DA-induced striatal death was significantly higher in neurons
overexpressing Exp-HTT than the wild-type HTT (P = 0.0035
between DA-treated HTT-expressing cells and DA-treated Exp-
HTT-expressing cells; Fig. 5B), thus illustrating the combined toxic-
ity of DA and Exp-HTT. As previously shown, the total knockdown
of D2R partially but significantly reversed this effect in Exp-HTT-
expressing cells (P = 0.0419). The effect of DA was similar in DA-
treated HTT and Exp-HTT-expressing cells in the presence of D2R
Total siRNA (P > 0.9999 non-significant). Of interest, the toxicity
induced by DA in Exp-HTT-expressing cells was not modified by
D2R Long siRNA (P = 0.0144), data that confirm a specific role of
D2R Short in DA-mediated toxicity (Fig. 5B).
Discussion
In striatal neurons, we previously showed a coupling between D2R
and the RhoA/ROCK signaling pathway (Deyts et al., 2009). Here
we extend these observations and provide evidence for a specific
coupling of D2R Short to this pathway, which affects striatal vulner-
ability to Exp-HTT.
Rho-associated kinases (ROCKs) are Ser/Thr protein kinases and
downstream effectors of the small GTPases RhoA. They are impor-
tant regulators of cell growth, migration, and apoptosis via the con-
trol of actin cytoskeletal assembly (for review Julian & Olson,
2014). In the context of HD, it has been shown that inhibitors of
ROCK decrease Exp-HTT aggregation formation (Burnett et al.,
2008; Bauer et al., 2009, 2012) and activates the proteasome
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Fig. 5. DA-induced potentiation of Exp-HTT mediated toxicity is linked to
D2R Short stimulation in striatal neurons. GFP-tagged Huntingtin (HTT)
constructs of wild-type HTT (25Q-HTT) and Exp-HTT (103Q-HTT) were
transfected in striatal neurons. (A) Quantification of DA-induced increase of
aggregates in striatal neurons co-transfected with Exp-HTT and siRNAs
(Control, D2R Long, or D2R Total; DA 100 lM). (B) Quantifications of the
percentage of cell survival in striatal neurons co-transfected with siRNAs
(Control, D2R Long, or D2R Total) and HTT (left panel) or Exp-HTT (right
panel) was measured 24 h after DA (100 lM) based on Hoechst labeling.
Data are expressed as mean  SEM from three independent experiments
(100 transfected neurons per condition and experiment). Statistical analyses
were performed using two-way ANOVA followed by Bonferroni’s post hoc
analysis. ###P < 0.001; ##P < 0.005; #P < 0.05 when comparing untreated
HTT and Exp-HTT-expressing cells. $$P < 0.005 when comparing DA-trea-
ted HTT- and Exp-HTT-expressing cells. *P < 0.05, ***P < 0.001, when
comparing Exp-HTT-expressing cells treated or not with DA. οP < 0.05,
when comparing DA-treated Exp-HTT-expressing cells in the presence of
Control siRNA and D2R Total siRNA.
Fig. 6. Schematic representation of DA-mediated toxicity and striatal vul-
nerability in HD. During aging, DA auto-oxidation potentiates pro-apoptotic
pathways that are activated by Exp-HTT (Charvin et al., 2005; Garcia et al.,
2004). By acting on D2R Short isoform, DA also activates the Rho/ROCK
pathway, which potentiates Exp-HTT aggregate formation and neuronal
death, two features of the pathogenesis of the disease. As a result, DA shows
a dual implication in Exp-HTT-mediated toxicity.
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degradation pathways (Bauer et al., 2009). This pathway is signifi-
cantly enriched in large-scale HTT-interacting protein networks and
has been proposed as a modifier of Exp-HTT (Shirasaki et al.,
2012; Tourette et al., 2014). Rho/ROCK inhibition using pharmaco-
logical or molecular approaches reduces the aggregation and toxicity
of proteins with expanded glutamine including HTT (Bauer et al.,
2009, 2012), androgen receptor in drosophila, or cell line models
(Pollitt et al., 2003). Inhibition of Rho/ROCK pathway also shows
benefits in Alzheimer disease (Hahmann & Schroeter, 2010; Li
et al., 2013) as well as in other neurodegenerative diseases (for
review Hensel et al., 2015). Cofilin is a well-known substrate of
Rho/ROCK pathway and is required for the actin cytoskeleton
dynamics and reorganization of actin filaments (Bamburg & Wig-
gan, 2002). Cofilin phosphorylation participates in neuronal dystro-
phy induced by beta-amyloid in Alzheimer’s disease pathology
(Heredia et al., 2006). In striatal neurons in culture, the inhibition of
ROCK reversed D2R-mediated phosphorylation of cofilin, along
with Exp-HTT-induced aggregate formation, neuritic retraction, and
neuronal death (Deyts et al., 2009). Importantly, we show here that
the coupling of D2R to RhoA/ROCK is specific of the Short,
spliced version of D2R.
The molecular mechanisms at the origin of the D2R Short-
mediated activation of Rho remain to be established. One candidate
could be the scaffolding protein b-arrestin2, which facilitates some
facets of D2R signaling, in addition to its canonical role in receptor
internalization (Beaulieu et al., 2005). Specific role of b-Arrestin2
in D2R Short, but not D2R Long-mediated ERK activation, has
been described (Kim et al., 2004). On the other hand, b-arrestins,
which interact with the exchange factor for RhoGTPases PDZ-Rho-
GEF (Oleksy et al., 2006), are associated with the activation of Rho
downstream the Angiotensin A2 receptors (Barnes et al., 2005).
The first neuronal population affected in HD is the D2R express-
ing medium spiny neurons (MSNs; Roze et al., 2010). In mice and
human, neuropil aggregates appear first in the globus pallidus and
the substantia nigra, two brain regions where D2R are enriched
(Albin et al., 1992; Li et al., 2001). Locally they are thought to be
toxic by poisoning the axonal transport (Li et al., 2001; Lee et al.,
2004). Based on the present work, we propose that Exp-HTT-
induced toxicity is exaggerated by DA via two routes (see Fig. 6):
one involves auto-oxidation of DA (Luo et al., 1998) and potentia-
tion of pro-apoptotic pathways that are activated by Exp-HTT (Gar-
cia et al., 2004; Charvin et al., 2005). The other one is associated
with the stimulation of D2R Short isoform, which is coupled to the
activation of the Rho-ROCK signaling pathway, the formation of
aggregates, and neuronal death.
In addition to its important role in striatal vulnerability in HD,
alterations of D2R-dependent signaling have been implicated in
other brain pathologies such as schizophrenia, attention deficit
hyperactivity disorder, Tourette syndrome, obsessive–compulsive
disorder, Parkinson’s disease, and drug addiction (Iversen & Iversen,
2007; Seeman, 2010). The identification of D2Rs isoforms involved
in these pathologies is of crucial importance for the development of
new therapy. Herein, we provide evidence that interfering with D2R
Short coupling to Rho might constitute a new and promising thera-
peutic strategy in HD and probably other brain pathologies.
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